Benzinga | Jun 16, 2021 07:51AM EDT

BioCryst's Orladeyo Application Under Review In Israel For Hereditary Angioedema

* The Israeli Ministry of Health has accepted for review BioCryst Pharmaceuticals Inc's (NASDAQ:BCRX) application for Orladeyo to prevent recurrent attacks in patients with hereditary angioedema (HAE) 12 years and older.

* The Israeli Ministry of Health also has granted an accelerated review.

* In addition, BioCryst has entered into a distribution and supply agreement granting Neopharm Ltd to commercialize Orladeyo in Israel.

* Price Action: BCRX shares are up 1.6% at $15.86 during the premarket session on the last check Wednesday.